High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
暂无分享,去创建一个
G. Morgan | M. Drayson | F. Davies | P. Selby | J. Child | Peter J Selby | R. Owen | Gareth J Morgan | Faith E Davies | Roger G Owen | J Anthony Child | Susan E Bell | Kim Hawkins | Julia Brown | Mark T Drayson | K. Hawkins | Julia Brown | S. Bell
[1] A. Newland,et al. INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA , 1989, The Lancet.
[2] J. Baars,et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. , 2002, Blood.
[3] G. Morgan,et al. Autologous stem cell transplantation for malignancy: a systematic review of the literature. , 2000, Clinical and laboratory haematology.
[4] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[5] D. Vesole,et al. High-dose therapy in multiple myeloma. , 2003, Blood.
[6] T. Mcelwain,et al. HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.
[7] G. Morgan,et al. The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma , 2001, British journal of haematology.
[8] R. Bataille,et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.
[9] B. Barlogie,et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.
[10] P. Ravaud,et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.
[11] I. Maclennan,et al. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis , 1992, The Lancet.
[12] T. Hickish,et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Johnsen,et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. , 2000, Blood.
[14] B. Barlogie,et al. Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants , 2002, British journal of haematology.
[15] J. Child. EVOLVING STRATEGIES FOR THE TREATMENT OF MYELOMATOSIS , 1994, British journal of haematology.
[16] B. Barlogie,et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.
[17] J. Cuzick,et al. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. , 1985, British Journal of Cancer.
[18] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[19] M. Slevin,et al. Multiple myeloma treated with high dose intravenous melphalan , 1987, British journal of haematology.
[20] J. San-Miguel,et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients , 2000, British journal of haematology.
[21] K. Fields,et al. High-Dose Therapy and Stem Cell Transplantation. , 1998, Cancer control : journal of the Moffitt Cancer Center.
[22] M. Gore,et al. INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION , 1989, The Lancet.
[23] E. Montserrat,et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.